RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
THCRX
Price
$29.35
Change
-$0.16 (-0.54%)
Updated
Sep 20 closing price
Ad is loading...

RPTIX vs THCRX

Header iconRPTIX vs THCRX Comparison
Open Charts RPTIX vs THCRXBanner chart's image
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
Thornburg Small/Mid Cap Growth R3
Price$29.35
Change-$0.16 (-0.54%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RPTIX vs THCRX Comparison Chart
Loading...
VS
RPTIX vs. THCRX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a StrongBuy and THCRX is a Buy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. THCRX (276M). RPTIX pays higher dividends than THCRX: RPTIX (0.18) vs THCRX (0.00). RPTIX was incepted earlier than THCRX: RPTIX (9 years) vs THCRX (21 years). THCRX is a more actively managed with annual turnover of: 57.56 vs. RPTIX (21.70). THCRX has a lower initial minimum investment than RPTIX: THCRX (0) vs RPTIX (500000). THCRX annual gain was more profitable for investors over the last year : 24.58 vs. RPTIX (14.81). RPTIX return over 5 years is better than : 15.09 vs. THCRX (-26.66).
RPTIXTHCRXRPTIX / THCRX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years21 years-
Gain YTD9.12715.32460%
Front LoadN/AN/A-
Min. Initial Investment5000000-
Min. Initial Investment IRAN/AN/A-
Net Assets31.4B276M11,377%
Annual Yield % from dividends0.180.00-
Returns for 1 year14.8124.5860%
Returns for 3 years-13.57-44.2531%
Returns for 5 years15.09-26.66-57%
Returns for 10 yearsN/A10.80-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp